Optom Vis Sci. 2022 Jul 1;99(7):589-592. doi: 10.1097/OPX.0000000000001904. Epub 2022 Apr 13.
Rho-associated kinase inhibitors have been used in glaucoma management for reducing intraocular pressure. Their role in treating corneal endothelial damage and promoting corneal epithelial healing has also been reported. Presented is a case report demonstrating healing of a previously nonresponsive neurotrophic ulcer with addition of the Rho-associated kinase inhibitor, netarsudil.
Early in vitro -based research on corneal application of Rho-associated kinase inhibitors has shown these molecules to be beneficial to corneal epithelial wound healing. The presented case supports their use in epithelial disease. It is the author's hope that this will inspire further investigation.
Presented here is a case report describing the use of netarsudil, a Rho-associated kinase inhibitor in the management of a neurotrophic corneal ulcer that was nonresponsive to frontline therapy. The application of netarsudil was followed by rapid healing of the defect, although a concomitant increase in mucous production was also noted.
This case supports the use of netarsudil as an agonist of epithelial healing, although further research is needed.
Rho 相关激酶抑制剂已被用于青光眼治疗,以降低眼内压。它们在治疗角膜内皮损伤和促进角膜上皮愈合方面的作用也有报道。本文报告了一例病例,表明 Rho 相关激酶抑制剂奈立定的加入可治愈先前对神经营养性溃疡无反应的溃疡。
早期基于体外的角膜应用 Rho 相关激酶抑制剂的研究表明,这些分子有利于角膜上皮伤口愈合。本报告中的病例支持它们在治疗上皮疾病中的应用。作者希望这将激发进一步的研究。
本文报告了一例使用奈立定(一种 Rho 相关激酶抑制剂)治疗对一线治疗无反应的神经营养性角膜溃疡的病例。奈立定的应用后,缺损迅速愈合,但同时也注意到黏液分泌增加。
尽管需要进一步的研究,但该病例支持奈立定作为上皮愈合激动剂的使用。